Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DRL_AB · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| DRL_AB 125 mg via AI | EXPERIMENTAL | Participants will receive a single subcutaneous (SC) dose of DRL\_AB, 125 milligrams (mg) in an AI on Day 1 of the treatment period of 70 days. |
| DRL_AB 125 mg via PFS | ACTIVE_COMPARATOR | Participants will receive a single SC dose of DRL\_AB, 125 mg in a PFS on Day 1 of the treatment period of 70 days. |
| Name | Type | Description |
|---|---|---|
| DRL_AB | BIOLOGICAL | DRL\_AB administered as a SC injection. |
Inclusion Criteria: 1. Healthy male volunteers aged 18 to 50 years (both inclusive) at the time of signing informed consent form. 2. Ability and amenability to provide written informed consent to participate in the study and adhere to study requirements. 3. Body mass index in the range 18.5-30.0 ki...
DRL_AB is an investigational monoclonal antibody being developed by Dr. Reddy's Laboratories Ltd. It is currently in Phase 1 clinical development for use in healthy volunteers. The drug is being studied in a clinical trial to evaluate its pharmacokinetics in healthy male participants.
DRL_AB is a monoclonal antibody, but its specific molecular target has not been disclosed. The drug is being studied in healthy volunteers to evaluate its pharmacokinetics, which includes how the body absorbs, distributes, metabolizes, and excretes the drug.
DRL_AB is being developed by Dr. Reddy's Laboratories Ltd, a pharmaceutical company listed on the stock exchange under the ticker symbol RDY. The company is conducting a Phase 1 clinical trial to evaluate the drug's pharmacokinetics in healthy male participants.
DRL_AB is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing Phase 1 trial is designed to evaluate the pharmacokinetics of DRL_AB in healthy male participants.
DRL_AB is being studied in a Phase 1 clinical trial with the identifier NCT07744828. The trial is titled 'A Study to Evaluate Pharmacokinetics of DRL_AB in Healthy Male Participants' and is planned to enroll 160 healthy male participants in New Zealand. The trial is not yet recruiting.
No alternative names for DRL_AB have been disclosed. The drug is being developed under the code name DRL_AB by Dr. Reddy's Laboratories Ltd and is currently in Phase 1 clinical trials for healthy volunteers.